Brent Warner - Mar 1, 2024 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role: President, Gene Therapy
Signature: /s/ Harry J.Leonhardt, Attorney-in-Fact
Stock symbol: PSTX
Transactions as of: Mar 1, 2024
Transactions value $: -$147,602
Form type: 4
Date filed: 3/4/2024, 05:18 PM
Previous filing: Mar 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Award	$0	+80.7K	+21.59%	$0.00	455K	Mar 1, 2024	Direct	F1
transaction	PSTX	Common Stock	Tax liability	-$148K	-35.7K	-7.86%	$4.13	419K	Mar 1, 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Employee Stock Option (Right to Buy)	Award	$0	+112K		$0.00	112K	Mar 1, 2024	Common Stock	112K	$4.13	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
F2	Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on March 1, 2022 and March 1, 2023.
F3	12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.